Cannabinoids in treatment of resistant Epilepsy

The interest in Cannabis-based products for the treatment of refractory epilepsy has skyrocketed in recent years. Treatment-resistant epilepsy (TRE) affects 30% of epilepsy patients and is associated with severe morbidity and increased mortality. Cannabis-based therapies have been used to treat epilepsy for millennia, but only in the last few years have we begun to collect data from adequately powered Placebo-controlled, Randomized trials (RCTs) with Cannabidiol (CBD), a cannabis derivative.

 

    Related Conference of Cannabinoids in treatment of resistant Epilepsy

    Cannabinoids in treatment of resistant Epilepsy Conference Speakers